| scholarly article | Q13442814 |
| P50 | author | Camillo Porta | Q37393105 |
| P2093 | author name string | Giovanni Gaudino | |
| Luciano Mutti | |||
| Dario Barbone | |||
| Sara Busacca | |||
| Pietro Bertino | |||
| Serena Germano | |||
| Sabrina Pinato | |||
| Roberto Favoni | |||
| Giancarlo Tassi | |||
| P2860 | cites work | The European mesothelioma epidemic | Q24650064 |
| Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
| Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor | Q27824804 | ||
| Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment | Q28188301 | ||
| Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells | Q28279744 | ||
| Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma | Q33220994 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma | Q33946963 | ||
| Drug synergism: its detection and applications | Q34337018 | ||
| Platelet-derived growth factor receptors: a therapeutic target in solid tumors | Q34461490 | ||
| Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. | Q34589774 | ||
| An overview of targeted treatments in cancer | Q35544746 | ||
| The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature | Q35746576 | ||
| Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma | Q35839893 | ||
| Pleural mesothelioma: little evidence, still time to do trials | Q35903121 | ||
| Targeted cancer therapy | Q35953128 | ||
| Statistical analysis of drug combinations for synergism | Q36155427 | ||
| New agents in the management of advanced mesothelioma. | Q36179396 | ||
| Platelet-derived growth factor (PDGF) and glial tumorigenesis | Q36247732 | ||
| c-Kit is not expressed in malignant mesothelioma | Q38451233 | ||
| Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. | Q40200594 | ||
| FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. | Q40371743 | ||
| Biological and immunological aspects of malignant mesothelioma | Q40476744 | ||
| Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. | Q40502632 | ||
| Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. | Q40593401 | ||
| Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression | Q40601630 | ||
| STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake | Q40632066 | ||
| The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor | Q40755750 | ||
| The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth | Q40859298 | ||
| Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? | Q41072033 | ||
| Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines | Q41229288 | ||
| Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma | Q43558001 | ||
| Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells | Q44150480 | ||
| Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial | Q46541600 | ||
| SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. | Q53854583 | ||
| Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1 | Q67802477 | ||
| Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 | Q74083395 | ||
| Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies | Q74317144 | ||
| Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor | Q74428792 | ||
| Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction | Q77746897 | ||
| Malignant pleural mesothelioma | Q80200957 | ||
| Chemotherapy for malignant pleural mesothelioma: past results and recent developments | Q80355524 | ||
| Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma | Q83197781 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | imatinib | Q177094 |
| P304 | page(s) | 690-695 | |
| P577 | publication date | 2007-02-20 | |
| P1433 | published in | Thorax | Q7796158 |
| P1476 | title | Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed | |
| P478 | volume | 62 |
| Q36988077 | A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q38004067 | Anti-angiogenic therapies for malignant pleural mesothelioma |
| Q36874759 | Fowlpox-based survivin vaccination for malignant mesothelioma therapy |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q51823843 | Immunotherapy advances for mesothelioma treatment. |
| Q37672887 | Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors |
| Q38706374 | Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. |
| Q34293068 | Investigational approaches for mesothelioma |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q26800042 | Mesothelioma treatment: Are we on target? A review |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q52672878 | Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. |
| Q39380409 | PDGF-D/PDGF-ββ receptor-regulated chemotaxis of malignant mesothelioma cells |
| Q33442594 | Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). |
| Q37367634 | Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma |
| Q36337646 | Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509 |
| Q36159154 | Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q52672891 | Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q57469068 | p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification |
Search more.